Medicines

Fulltext search

For help on how to get the results you want, see our search tips.

Search results

391 results

Medicine European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter Referrals Remove Referrals filter

Medicine type Generic Remove Generic filter Exceptional circumstances Remove Exceptional circumstances filter Biosimilar Remove Biosimilar filter

Categories Human Remove Human filter Veterinary Remove Veterinary filter

Sort by

List item

Human medicine European public assessment report (EPAR): Aybintio

bevacizumab, Colorectal Neoplasms, Breast Neoplasms, Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms
Date of authorisation: 19/08/2020, , , Revision: 1, Authorised, Last updated: 09/12/2020
List item

Human medicine European public assessment report (EPAR): Azacitidine Accord

azacitidine, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic, Leukemia, Myeloid, Acute
Date of authorisation: 13/02/2020, , Authorised, Last updated: 21/02/2020
List item

Human medicine European public assessment report (EPAR): Azacitidine betapharm

azacitidine, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic, Leukemia, Myeloid, Acute
Date of authorisation: 24/03/2020, , Revision: 1, Authorised, Last updated: 20/11/2020
List item

Human medicine European public assessment report (EPAR): Azacitidine Mylan

azacitidine, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic, Leukemia, Myeloid, Acute
Date of authorisation: 27/03/2020, , Revision: 1, Authorised, Last updated: 16/09/2020
List item

Human medicine European public assessment report (EPAR): Bemfola

follitropin alfa, Anovulation
Date of authorisation: 26/03/2014, , Revision: 8, Authorised, Last updated: 10/01/2019
List item

Human medicine European public assessment report (EPAR): Benepali

etanercept, Arthritis, Psoriatic, Arthritis, Rheumatoid, Psoriasis
Date of authorisation: 13/01/2016, , Revision: 12, Authorised, Last updated: 30/11/2020
List item

Human medicine European public assessment report (EPAR): Binocrit

epoetin alfa, Anemia, Kidney Failure, Chronic
Date of authorisation: 28/08/2007, , Revision: 20, Authorised, Last updated: 31/10/2019
List item

Human medicine European public assessment report (EPAR): Biograstim

filgrastim, Neutropenia, Hematopoietic Stem Cell Transplantation, Cancer
Date of authorisation: 15/09/2008, , Revision: 8, Withdrawn, Last updated: 19/01/2017
List item

Human medicine European public assessment report (EPAR): Blitzima (updated)

rituximab, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell
Date of authorisation: 13/07/2017, , , Revision: 9, Authorised, Last updated: 07/01/2021
List item

Human medicine European public assessment report (EPAR): Bortezomib Accord

bortezomib, Multiple Myeloma
Date of authorisation: 20/07/2015, , Revision: 7, Authorised, Last updated: 09/06/2020
List item

Human medicine European public assessment report (EPAR): Bortezomib Fresenius Kabi

bortezomib, Multiple Myeloma
Date of authorisation: 14/11/2019, , Revision: 3, Authorised, Last updated: 02/12/2020
List item

Human medicine European public assessment report (EPAR): Bortezomib Hospira

bortezomib, Multiple Myeloma
Date of authorisation: 22/07/2016, , Revision: 9, Authorised, Last updated: 19/10/2020
List item

Human medicine European public assessment report (EPAR): Bortezomib Sun

bortezomib, Multiple Myeloma
Date of authorisation: 22/07/2016, , Revision: 9, Authorised, Last updated: 18/11/2020
List item

Human medicine European public assessment report (EPAR): Brineura

cerliponase alfa, Neuronal Ceroid-Lipofuscinoses
Date of authorisation: 30/05/2017, , , , , Revision: 4, Authorised, Last updated: 12/06/2020
List item

Human medicine European public assessment report (EPAR): Busulfan Fresenius Kabi (updated)

busulfan, Hematopoietic Stem Cell Transplantation
Date of authorisation: 22/09/2014, , Revision: 8, Authorised, Last updated: 15/01/2021
List item

Human medicine European public assessment report (EPAR): Cabazitaxel Accord

cabazitaxel, Prostatic Neoplasms, Castration-Resistant
Date of authorisation: 28/08/2020, , , Authorised, Last updated: 28/10/2020
List item

Human medicine European public assessment report (EPAR): Capecitabine Accord

capecitabine, Colonic Neoplasms, Breast Neoplasms, Colorectal Neoplasms, Stomach Neoplasms
Date of authorisation: 20/04/2012, , , Revision: 12, Authorised, Last updated: 03/08/2020
List item

Human medicine European public assessment report (EPAR): Capecitabine Medac

capecitabine, Colorectal Neoplasms
Date of authorisation: 19/11/2012, , , Revision: 10, Authorised, Last updated: 05/08/2020
List item

Human medicine European public assessment report (EPAR): Capecitabine SUN

capecitabine, Stomach Neoplasms, Breast Neoplasms, Colonic Neoplasms, Colorectal Neoplasms
Date of authorisation: 21/06/2013, , Revision: 3, Withdrawn, Last updated: 22/12/2016
List item

Human medicine European public assessment report (EPAR): Capecitabine Teva

capecitabine, Colonic Neoplasms, Breast Neoplasms, Colorectal Neoplasms, Stomach Neoplasms
Date of authorisation: 20/04/2012, , , Revision: 13, Authorised, Last updated: 29/07/2020
List item

Human medicine European public assessment report (EPAR): Carmustine Obvius

carmustine, Hodgkin Disease, Lymphoma, Non-Hodgkin
Date of authorisation: 18/07/2018, , Revision: 5, Authorised, Last updated: 21/10/2020
List item

Human medicine European public assessment report (EPAR): Caspofungin Accord

caspofungin acetate, Candidiasis, Aspergillosis
Date of authorisation: 11/02/2016, , Revision: 6, Authorised, Last updated: 05/03/2020
List item

Human medicine European public assessment report (EPAR): Cegfila (previously Pegfilgrastim Mundipharma)

pegfilgrastim, Neutropenia
Date of authorisation: 19/12/2019, , , Revision: 4, Authorised, Last updated: 27/10/2020
List item

Human medicine European public assessment report (EPAR): Ceplene

Histamine dihydrochloride, Leukemia, Myeloid, Acute
Date of authorisation: 07/10/2008, , , Revision: 12, Authorised, Last updated: 01/08/2018
List item

Human medicine European public assessment report (EPAR): Chenodeoxycholic acid Leadiant (previously known as Chenodeoxycholic acid sigma-tau)

Chenodeoxycholic acid, Xanthomatosis, Cerebrotendinous, Metabolism, Inborn Errors
Date of authorisation: 10/04/2017, , , , Revision: 3, Authorised, Last updated: 24/11/2017